BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Khan RS, Newsome PN. Non-alcoholic fatty liver disease and liver transplantation. Metabolism. 2016;65:1208-1223. [PMID: 26997540 DOI: 10.1016/j.metabol.2016.02.013] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Polyzos SA, Bugianesi E, Kountouras J, Mantzoros CS. Nonalcoholic fatty liver disease: Updates on associations with the metabolic syndrome and lipid profile and effects of treatment with PPAR-γ agonists. Metabolism 2017;66:64-8. [PMID: 27594084 DOI: 10.1016/j.metabol.2016.08.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
2 Duan X, Meng Q, Wang C, Liu Z, Liu Q, Sun H, Sun P, Yang X, Huo X, Peng J, Liu K. Calycosin attenuates triglyceride accumulation and hepatic fibrosis in murine model of non-alcoholic steatohepatitis via activating farnesoid X receptor. Phytomedicine 2017;25:83-92. [PMID: 28190475 DOI: 10.1016/j.phymed.2016.12.006] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
3 El Hadi H, Vettor R, Rossato M. Vitamin E as a Treatment for Nonalcoholic Fatty Liver Disease: Reality or Myth? Antioxidants (Basel) 2018;7:E12. [PMID: 29337849 DOI: 10.3390/antiox7010012] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 14.0] [Reference Citation Analysis]
4 Drescher HK, Schumacher F, Schenker T, Baues M, Lammers T, Hieronymus T, Trautwein C, Streetz KL, Kroy DC. c-Met Signaling Protects from Nonalcoholic Steatohepatitis- (NASH-) Induced Fibrosis in Different Liver Cell Types. Oxid Med Cell Longev 2018;2018:6957497. [PMID: 30538805 DOI: 10.1155/2018/6957497] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
5 Polyzos SA, Mantzoros CS. Nonalcoholic fatty future disease. Metabolism 2016;65:1007-16. [DOI: 10.1016/j.metabol.2015.12.009] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 7.6] [Reference Citation Analysis]
6 Sanchez-Torrijos Y, Ampuero J, Romero-Gómez M. Cardiovascular assessment in liver transplant for non-alcoholic steatohepatitis patients: What we do, what we should do. World J Hepatol 2017; 9(15): 697-703 [PMID: 28596817 DOI: 10.4254/wjh.v9.i15.697] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
7 Mintziori G, Polyzos SA. Emerging and future therapies for nonalcoholic steatohepatitis in adults. Expert Opinion on Pharmacotherapy 2016;17:1937-46. [DOI: 10.1080/14656566.2016.1225727] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 5.4] [Reference Citation Analysis]
8 Lanthier N. Les nouveaux traitements de la stéatohépatite non-alcoolique. Nutrition Clinique et Métabolisme 2020;34:216-22. [DOI: 10.1016/j.nupar.2020.04.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Polyzos SA, Kang ES, Boutari C, Rhee E, Mantzoros CS. Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis. Metabolism 2020;111:154203. [DOI: 10.1016/j.metabol.2020.154203] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 35.0] [Reference Citation Analysis]
10 Bouazizi K, Zarai M, Marquet F, Aron-Wisnewsky J, Clément K, Redheuil A, Kachenoura N. Adipose tissue fibrosis assessed by high resolution ex vivo MRI as a hallmark of tissue alteration in morbid obesity. Quant Imaging Med Surg 2021;11:2162-8. [PMID: 33936996 DOI: 10.21037/qims-20-879] [Reference Citation Analysis]
11 Tucker B, Li H, Long X, Rye K, Ong KL. Fibroblast growth factor 21 in non-alcoholic fatty liver disease. Metabolism 2019;101:153994. [DOI: 10.1016/j.metabol.2019.153994] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
12 Pisano G, Fracanzani AL, Caccamo L, Donato MF, Fargion S. Cardiovascular risk after orthotopic liver transplantation, a review of the literature and preliminary results of a prospective study. World J Gastroenterol 2016; 22(40): 8869-8882 [PMID: 27833378 DOI: 10.3748/wjg.v22.i40.8869] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
13 Poulos JE, Kalogerinis PT, Milanov V, Kalogerinis CT, Poulos EJ. The Effects of Vitamin E, Silymarin and Carnitine on the Metabolic Abnormalities Associated with Nonalcoholic Liver Disease. J Diet Suppl 2021;:1-16. [PMID: 33491528 DOI: 10.1080/19390211.2021.1874587] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Venetsanaki V, Polyzos SA. Menopause and Non-Alcoholic Fatty Liver Disease: A Review Focusing on Therapeutic Perspectives. Curr Vasc Pharmacol. 2019;17:546-555. [PMID: 29992886 DOI: 10.2174/1570161116666180711121949] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 20.0] [Reference Citation Analysis]
15 Tada T, Nishimura T, Yoshida M, Iijima H. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: new trends and role of ultrasonography. J Med Ultrasonics 2020;47:511-20. [DOI: 10.1007/s10396-020-01058-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
16 Pastori D, Baratta F, Novo M, Cocomello N, Violi F, Angelico F, Del Ben M. Remnant Lipoprotein Cholesterol and Cardiovascular and Cerebrovascular Events in Patients with Non-Alcoholic Fatty Liver Disease. J Clin Med. 2018;7. [PMID: 30360566 DOI: 10.3390/jcm7110378] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
17 Li S, Takahara T, Fujino M, Fukuhara Y, Sugiyama T, Li XK, Takahara S. Astaxanthin prevents ischemia-reperfusion injury of the steatotic liver in mice. PLoS One 2017;12:e0187810. [PMID: 29121675 DOI: 10.1371/journal.pone.0187810] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 6.8] [Reference Citation Analysis]
18 Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, Harrison SA, Brunt EM, Sanyal AJ. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67:328-357. [PMID: 28714183 DOI: 10.1002/hep.29367] [Cited by in Crossref: 1978] [Cited by in F6Publishing: 1817] [Article Influence: 494.5] [Reference Citation Analysis]
19 Samji NS, Heda R, Satapathy SK. Peri-transplant management of nonalcoholic fatty liver disease in liver transplant candidates . Transl Gastroenterol Hepatol 2020;5:10. [PMID: 32190778 DOI: 10.21037/tgh.2019.09.09] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
20 Iannucci LF, Cioffi F, Senese R, Goglia F, Lanni A, Yen PM, Sinha RA. Metabolomic analysis shows differential hepatic effects of T2 and T3 in rats after short-term feeding with high fat diet. Sci Rep 2017;7:2023. [PMID: 28515456 DOI: 10.1038/s41598-017-02205-1] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 5.8] [Reference Citation Analysis]
21 Kaufmann B, Reca A, Wang B, Friess H, Feldstein AE, Hartmann D. Mechanisms of nonalcoholic fatty liver disease and implications for surgery. Langenbecks Arch Surg 2021;406:1-17. [PMID: 32833053 DOI: 10.1007/s00423-020-01965-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
22 Møller S, Danielsen KV, Wiese S, Hove JD, Bendtsen F. An update on cirrhotic cardiomyopathy. Expert Rev Gastroenterol Hepatol 2019;13:497-505. [PMID: 30802157 DOI: 10.1080/17474124.2019.1587293] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
23 Pisano G, Donato MF, Consonni D, Oberti G, Borroni V, Lombardi R, Invernizzi F, Bertelli C, Caccamo L, Porzio M, Dondossola D, Rossi G, Fargion S, Fracanzani AL. High prevalence of early atherosclerotic and cardiac damage in patients undergoing liver transplantation: Preliminary results. Dig Liver Dis 2020;52:84-90. [PMID: 31521545 DOI: 10.1016/j.dld.2019.07.007] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
24 Liu H, Jayakumar S, Traboulsi M, Lee SS. Cirrhotic cardiomyopathy: Implications for liver transplantation. Liver Transpl. 2017;23:826-835. [PMID: 28407402 DOI: 10.1002/lt.24768] [Cited by in Crossref: 68] [Cited by in F6Publishing: 56] [Article Influence: 22.7] [Reference Citation Analysis]
25 Sibiya S, Msibi B, Khathi A, Sibiya N, Booysen I, Ngubane P. The effect of dioxidovanadium complex (V) on hepatic function in streptozotocin-induced diabetic rats. Can J Physiol Pharmacol 2019;97:1169-75. [PMID: 31491333 DOI: 10.1139/cjpp-2019-0369] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
26 Tiniakos DG, Anstee QM, Burt AD. Fatty Liver Disease. Macsween's Pathology of the Liver. Elsevier; 2018. pp. 308-71. [DOI: 10.1016/b978-0-7020-6697-9.00005-4] [Cited by in Crossref: 7] [Article Influence: 2.3] [Reference Citation Analysis]
27 van den Berg EH, Douwes RM, de Meijer VE, Schreuder TCMA, Blokzijl H. Liver transplantation for NASH cirrhosis is not performed at the expense of major post-operative morbidity. Dig Liver Dis. 2018;50:68-75. [PMID: 28935188 DOI: 10.1016/j.dld.2017.08.022] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
28 Li B, Zhang C, Zhan YT. Nonalcoholic Fatty Liver Disease Cirrhosis: A Review of Its Epidemiology, Risk Factors, Clinical Presentation, Diagnosis, Management, and Prognosis. Can J Gastroenterol Hepatol 2018;2018:2784537. [PMID: 30065915 DOI: 10.1155/2018/2784537] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 7.0] [Reference Citation Analysis]
29 Pastori D, Sciacqua A, Marcucci R, Del Ben M, Baratta F, Violi F, Pignatelli P; ATHERO-AF study group. Non-alcoholic fatty liver disease (NAFLD), metabolic syndrome and cardiovascular events in atrial fibrillation. A prospective multicenter cohort study. Intern Emerg Med 2021. [PMID: 33713286 DOI: 10.1007/s11739-021-02682-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]